YTHDF2 promotes ATP synthesis and immune evasion in B cell malignancies

Cell. 2025 Jan 23;188(2):331-351.e30. doi: 10.1016/j.cell.2024.11.007. Epub 2024 Dec 17.

Abstract

Long-term durable remission in patients with B cell malignancies following chimeric antigen receptor (CAR)-T cell immunotherapy remains unsatisfactory, often due to antigen escape. Malignant B cell transformation and oncogenic growth relies on efficient ATP synthesis, although the underlying mechanisms remain unclear. Here, we report that YTHDF2 facilitates energy supply and antigen escape in B cell malignancies, and its overexpression alone is sufficient to cause B cell transformation and tumorigenesis. Mechanistically, YTHDF2 functions as a dual reader where it stabilizes mRNAs as a 5-methylcytosine (m5C) reader via recruiting PABPC1, thereby enhancing their expression and ATP synthesis. Concomitantly, YTHDF2 also promotes immune evasion by destabilizing other mRNAs as an N6-methyladenosine (m6A) reader. Small-molecule-mediated targeting of YTHDF2 suppresses aggressive B cell malignancies and sensitizes them to CAR-T cell therapy.

Keywords: ATP production; B cell malignancies; CAR-T; CD19; MHC-II; YTHDF2; m(5)C; m(6)A; metabolism.

MeSH terms

  • 5-Methylcytosine / metabolism
  • Adenosine / analogs & derivatives
  • Adenosine Triphosphate* / biosynthesis
  • Adenosine Triphosphate* / metabolism
  • Animals
  • B-Lymphocytes / immunology
  • B-Lymphocytes / metabolism
  • Cell Line, Tumor
  • Cell Transformation, Neoplastic
  • Humans
  • Immune Evasion*
  • Immunotherapy, Adoptive
  • Mice
  • RNA, Messenger / metabolism
  • RNA-Binding Proteins* / genetics
  • RNA-Binding Proteins* / metabolism
  • Receptors, Chimeric Antigen / metabolism

Substances

  • Adenosine Triphosphate
  • RNA-Binding Proteins
  • YTHDF2 protein, human
  • N-methyladenosine
  • RNA, Messenger
  • 5-Methylcytosine
  • Receptors, Chimeric Antigen
  • Adenosine